Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Menen – page 111

1 845 clinical trials in Menen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Menen at a glance
1 845
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 845 trials in Menen

Open in trial search

Neoplasm

Not recruiting

Study of OMX-0407 for Patients with Previously Treated Unresectable Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:OMX-0407
  • Sponsor:iOmx Therapeutics AG

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Irbesartan
  • Sponsor:Travere Therapeutics Inc.

Cough

Not recruiting

Study on the Effects of Camlipixant in Adults with Refractory or Unexplained Chronic Cough

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Camlipixant
  • Sponsor:Bellus Health Inc.

Long-term Study of Sotatercept for Adults with Pulmonary Arterial Hypertension (PAH)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Study on the Effectiveness and Safety of Golcadomide and Rituximab for Patients with Newly Diagnosed Advanced Follicular Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Celgene Corp.

Study of Nivolumab for Children and Adults with Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Nivolumab
  • Sponsor:Institut Gustave Roussy

Study on the Effect of Low-Dose Aspirin in Preventing New or Recurrent Colorectal Polyps in Patients with Lynch Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Patients with Higher-Risk Chronic Myelomonocytic Leukemia (CMML)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Groupe Francophone Des Myelodysplasies

Study of decitabine and cedazuridine combination in patients with lower-risk myelodysplastic syndromes

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Malignant melanoma

Not recruiting

Study of MaaT013 (Fecal Transplantation) Combined with Ipilimumab and Nivolumab in Patients with Previously Untreated Melanoma

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Assistance Publique Hopitaux De Paris

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bayer AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Menen

What the registry says about research in the country

01 Advanced Lung Cancer Research

Investigating innovative treatments for Non-Small Cell Lung Cancer (NSCLC), with a focus on patients carrying specific genetic mutations like EGFR Exon 20 insertions. The research evaluates combination therapies using zipalertinib with traditional chemotherapy to improve treatment outcomes.

  • Targeted Therapy Development
  • Genetic Mutation Analysis
  • Combination Treatment Strategies

Studies aim to determine optimal dosing and measure progression-free survival rates in advanced cases.

02 Immunotherapy Research

Evaluating the effectiveness of therapeutic cancer vaccines compared to conventional chemotherapy in treating metastatic NSCLC patients. The research specifically focuses on patients with HLA-A2 positive phenotype who have experienced immunotherapy failure.

  • Cancer Vaccine Development
  • Treatment Resistance Studies
  • Overall Survival Analysis

Research aims to demonstrate improved survival outcomes using novel vaccine-based approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.